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Abstract: Recent years have seen the emergence of noninvasive ventilation (NIV) as an important 
tool for management of patients with acute exacerbation of chronic obstructive pulmonary disease 
(COPD). Several well conducted studies in the recent years have established its role in the initial, 
as well as later management of these patients. However, some grey areas remain. Moreover, 
data is emerging on the role of long term nocturnal NIV use in patients with very severe stable 
COPD. This review summarizes the evidence supporting the use of NIV in various stages of 
COPD, discuss the merits as well as demerits of this novel ventilatory strategy and highlight the 
grey areas in the current body of knowledge.
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Introduction
Chronic obstructive pulmonary disease (COPD) is chronic progressive airway disorder 
characterized by airﬂ  ow limitation that is not fully reversible or ﬁ  xed (GOLD 2003). 
The chronic downhill course is interspersed with episodes of acute inﬂ  ammation, 
often due to infections, that is termed as acute exacerbations of COPD (AECOPD) 
(McCrory et al 2001). COPD is a major health problem and one of the leading causes 
of mortality and morbidity among middle-aged and elderly people both in developed 
and developing countries. Moreover, the prevalence of COPD is increasing (Hurd 
2000) and is projected to rank number three amongst all the causes of loss of DALYS 
(disability adjusted life years) in India by the year 2020.
During the year 2000, approximately 24 million adults in United States had 
evidence of obstructive airway disease and it was one of the ten leading causes of 
death in USA (Eric et al 2001). COPD was responsible for 1.5 million emergency 
department visits, 726,000 hospitalizations, and 119,000 deaths (Mannino et al 
2002). Obviously, COPD puts an enormous economic burden on the society and this 
is especially true for exacerbations of the disease. Andersson and colleagues (2002) 
estimated that almost 35%–45% of the total per capita healthcare costs for COPD are 
account for by exacerbations alone. Severe exacerbations requiring hospitalizations 
are responsible for a major chunk of these costs and among these, treatment costs 
of those who require endotracheal intubation and assisted ventilation with intensive 
care unit (ICU) admission are largest. Moreover, there are several other hazards of 
endotracheal intubation itself such as increased risk of infections (commonly called 
ventilator-associated pneumonia) and tracheal stenosis. A signiﬁ  cant proportion of 
patients with AECOPD need ventilatory support although the reported ﬁ  gures in the 
literature have been highly variable and range from 9.8%–67.6% (Weiss and Hudson 
1994). Furthermore, patients with AECOPD as compared to other causes of acute 
respiratory failure tend to have higher rates of ventilator dependence, weaning failures, 
as well as reintubation (Schonhofer et al 2001).International Journal of COPD 2008:3(3) 352
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There is a need to develop novel approaches towards 
ventilatory management for patients with AECOPD. The 
advent of noninvasive ventilation (NIV) in recent years has 
revolutionized the management of patients with AECOPD 
at different stages. A succession of well conducted studies 
has established the role of NIV in the ventilatory manage-
ment both, initial as well as subsequent, of a large majority 
of patients with AECOPD. Further, NIV is ﬁ  nding utility 
in other spheres of management of patients with COPD. In 
this review we provide an update on the role of NIV in the 
management of patients at different stages of COPD. We 
focus on the body of evidence supporting the use of NIV, 
discuss the merits as well as demerits of this novel ventila-
tory strategy, and highlight the grey areas in the current body 
of knowledge.
History of NIV
The earliest description of use of NIV was in patients with 
respiratory failure secondary to neuromuscular disease. Ellis 
and colleagues (1987) published the seminal paper describing 
the use of positive pressure ventilation through a nasal mask 
in these patients during sleep. After the initial success, NIV 
was used widely in patients with various causes of chronic 
hypercapnic respiratory failure such as chest wall deformity, 
neuromuscular disease and central hypoventilation. This 
was eventually followed by use of NIV in patients with 
hypercapnic respiratory failure secondary to obstructive 
airway disease.
Technical aspects of NIV
Ventilator
The ventilator used for NIV is a small, handy and easily 
portable machine. Types and principles of modes available 
for use with NIV are similar to those of conventional ven-
tilators. Moreover, the newer conventional ventilators can 
also be used to deliver noninvasive ventilation. As a result, 
an ICU need not wait to procure an NIV ventilator, as this 
modality of ventilation can also be offered to patients with 
the conventional ventilator connected to a face mask. Both 
pressure-cycled and volume-cycled modes are available. The 
volume-cycled mode of ventilation gives a preset volume of 
air with each breath, irrespective of airway pressure. Patient 
tolerance with this mode is often poor and chances of air leak 
are higher (Fernandez et al 1993).
Pressure-cycled ventilation is the preferred mode. In 
this mode, a preset pressure is applied with inspiration and 
expiration. This could be either continuous positive airway 
pressure (CPAP) or bi-level positive airway pressure (BiPAP). 
While using CPAP, a pre-set pressure is delivered throughout 
the respiratory cycle. BiPAP uses an electrically powered 
microprocessor that provides continuous high ﬂ  ow positive 
airway pressure, which cycles between high and low positive 
pressures. It has been recommended that for an intensive care 
unit (ICU) with limited experience of NIV, a BiPAP is the ideal 
machine to start with. In this type of ventilator, a breath trig-
gered by the patient leads to initiation of ﬂ  ow from the ventila-
tor. The machine delivers a pre-set amount of pressure, which 
is known as inspiratory positive airway pressure (IPAP). Fall 
of ﬂ  ow generated by the patient below a preset limit is sensed 
by the ventilator, which results in termination of inspiration. In 
certain ventilators ﬂ  ow may be terminated after a certain time 
period. This is followed by expiratory positive airway pressure 
(EPAP) that is achieved by closure of the expiratory limb of 
the ventilator circuit once the airway pressure falls below the 
pressure set as EPAP. This results in maintenance of a positive 
pressure in the airways during expiration as well, similar to 
that used in the generation of positive end expiratory pressure 
(PEEP) in conventional ventilators.
Interface
The interface between machine and the patient is a tight-
ﬁ  tting mask that is made of silicon. This could be a nasal or 
a full-face mask, which is held in place by straps. The choice 
of mask depends upon comfort and compliance of patient as 
well as operator choice. The mask should be of the proper 
size so that it ﬁ  ts snugly and there is no air leak. (see steps of 
initiation of NIV, Table 1). Closure of mouth is required for 
ventilation to be effective when given through nasal mask. 
If leak through the mouth is large, NIV failure may occur. 
Table 1 Steps in initiation of noninvasive ventilation
•  Carefully select patient after excluding all contraindications
•  Shift patient in the intensive care unit
•  Record baseline clinical and arterial blood gas parameters
•   Explain the procedure to the patient and put the patient in reclining 
position (45°)
•  Select a well ﬁ  tting mask (preferably full face mask)
•  Familiarize the patient with the mask
•  Select the pressures (inspiratory and expiratory)
•  Connect the tubing to the interface
•  Hold the mask in place and commence ventilation
•   After ensuring patient comfort and synchrony secure the mask in 
place with straps
•  Reassess the patient and modify settings if required
•  Add supplemental oxygen to keep saturation above 90%
•   Step up pressures towards therapeutic end point while avoiding 
patient discomfort
•  Repeat clinical assessment and blood gas analysis at 1hourInternational Journal of COPD 2008:3(3) 353
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Similar problems may arise in patients who are compulsory 
mouth breathers. It is advisable to switch to a full-face mask 
in such patients. In addition to having obvious disadvantages, 
such as lack of ability to communicate as well as feed orally, 
a signiﬁ  cant number of patients may become claustrophobic 
because of this mask. Whichever mask is used, one must take 
precautions against the development of pressure sores. The 
bridge of the nose is a common site for the development of 
sores. An appropriate amount of cushioning at the site of 
contact with skin and intermittent periods of rest may help 
to prevent this complication.
Initial management of patients 
with AECOPD
The hallmark of AECOPD is a sudden and marked imbalance 
between respiratory load and capacity. The inciting event is 
a marked ﬂ  are up in inﬂ  ammation in the airways that leads 
to increased airway edema, bronchospasm, and increased 
sputum production. All these lead to an increase in the elastic 
and resistive loads and worsening of airﬂ  ow resistance, with 
consequent increase in the labor of breathing. Patients tend to 
respond with rapid, shallow, largely ineffective breaths that 
put them at disadvantage in terms of respiratory mechanics. 
There is increased dead space breathing, leading to further 
deterioration in alveolar ventilation. Moreover, severe airﬂ  ow 
resistance leads to dynamic hyperinﬂ  ation, which results in 
a ﬂ  attening of the diaphragm that further increases the work 
of breathing. The combination of these events distorts the 
respiratory mechanics to the extent where alveolar ventila-
tion is signiﬁ  cantly compromised. The result is a vicious 
cycle that, unless broken by some sort of respiratory support 
system, can be fatal. Clinically, these patients tend to be 
markedly tachypneic except in the advanced stages, when 
respiratory muscle fatigue and encephalopathy due to blood 
gas abnormalities sets in. Hypercapnic respiratory failure 
with concurrent hypoxemia and acidemia ensues leading to 
deterioration in body organ systems including the respiratory 
muscles themselves.
Obviously, one of the approaches towards managing 
these patients would be to ofﬂ  oad the respiratory muscles 
and reduce the respiratory work load, leading to improvement 
in the imbalance. Further, an increase in the tidal volume, 
alongside a reduction in respiratory rate with consequent 
augmentation of the alveolar ventilation, would also favor-
ably revert the markedly altered respiratory physiology. 
Speciﬁ  cally, NIV leads to ofﬂ  oading of inspiratory muscles, 
thereby reducing the work of breathing, and also leads to 
improvement in the tidal volume/minute ventilation, which 
eventually results in improvements in alveolar ventilation 
and amelioration in the hypercapnia and its consequent 
adverse effects. In addition, EPAP delivered through NIV 
helps in countering intrinsic positive end expiratory pres-
sure (iPEEP).
A large number of well conducted high quality trials have 
clearly established the role of NIV in acute management 
of patients with AECOPD. It has been found to reduce the 
incidence of requirement of endotracheal intubation, as well 
as improve ICU and hospital survival. Table 2 summarizes 
the trials conducted on patients with AECOPD. Meduri and 
colleagues (1989) were the earliest to evaluate use of NIV 
Table 2 Data supporting the use of NIV in patients with AECOPD
References  Technique  Subjects (cases/controls)  Need of Intubation  Mortality rate
Meduri et al 1989  Face mask  6  33.3%  Nil
Brochard et al 1990  Face mask  13/13  7.7%/84.6%  15.4%/15.4%
Meduri et al 1991  Face mask  18  27.7%  Nil
Marino et al 1991  Nasal mask  10  20%  Nil
Bott et al 1993  Nasal mask  30/30  4%/30%  10%/30%
Kramer et al 1995  Nasal mask  11/12  9%/73%  6%/13%
Brochard et al 1995  Face mask  43/42  26%/74%  9%/29%
Barbe et al 1996  Nasal mask  14/10  Nil/Nil  Nil/Nil
Celikel et al 1998  Face mask  15/15  6.6%/40%*  0%/6.6%
Plant et al 2000  Face mask  118/118  15%/27%  10%/20%
Martin et al 2000  Nasal mask  12/11  25%/45%  8%/9%
Squadrone et al 2000  Face mask  64/64  62.5%**  8%/17%
Khilnani et al 2002  Nasal mask  20/20  15%/60%  –
CRG 2005  Face mask  171/171  4.6%/15.2%  4%/7%
Note: Many of the earlier studies (Meduri et al 1989, 1991; Marino 1991) were uncontrolled studies; *Comparison between the two strategies was on the basis of success 
rates in terms of no requirement of invasive ventilation in NIV group and no requirement of NIV or invasive ventilation in standard therapy group; **This study compared 
relative effectiveness of NIV to endotracheal intubation with conventional mechanical ventilation and not medical therapy.
Abbreviations: AECOPD, acute exacerbations of chronic obstructive pulmonary disease; NIV, noninvasive ventilation.International Journal of COPD 2008:3(3) 354
Khilnani and Banga
in patients with AECOPD in an open label noncomparative 
study. They documented improvement in physiological 
abnormalities in these patients with respiratory failure sec-
ondary to exacerbation of COPD. This was followed by a 
study by Brochard and colleagues (1990) who compared the 
outcome of 13 patients managed by NIV with 13 matched 
historical controls. These studies were followed by several 
randomized trials that compared the strategy of early NIV use 
versus the standard medical therapy (see Table 2) (Meduri 
et al 1989; Brochard et al 1990; Meduri et al 1991; Marino 
1991; Bott et al 1993; Kramer et al 1995; Brochard et al 
1995; Barbe et al 1996; Celikel et al 1998; Plant et al 2000; 
Martin et al 2000; Khilnani et al 2002; Squadrone et al 2004; 
Collaborative Research Group of Noninvasive Mechanical 
Ventilation for Chronic Obstructive Pulmonary Disease 
2005). Most of these studies have been positive trials, and 
showed that early institution of NIV lead to relief in dyspnea 
(Bott et al 1993), favorable improvements in blood gas abnor-
malities (Bott et al 1993; Kramer et al 1995; Brochard et al 
1995; Celikel et al 1998; Plant et al 2000) and reductions in 
the need for endotracheal intubation (Bott et al 1993; Kramer 
et al 1995; Brochard et al 1995; Plant et al 2000; Collabora-
tive Research Group of Noninvasive Mechanical Ventilation 
for Chronic Obstructive Pulmonary Disease 2005), ICU and 
hospital stay (Brochard et al 1990; Celikel et al 1998) as well 
as mortality (Bott et al 1993; Kramer et al 1995; Brochard 
et al 1995; Celikel et al 1998; Martin et al 2000).
The experience with the use of NIV in the initial man-
agement of patients with AECOPD at our center has also 
been positive (Khilnani et al 2002). Recent meta-analyses 
also found NIV to result in improvements in physiological 
variables as well as reduction in the need for intubation, dura-
tion of hospital stay and mortality (Keenan et al 2003; Ram 
et al 2004). Obviously, there is no controversy on the role 
of NIV in the early management of patients with AECOPD 
and should be a standard of care. However, the data on use 
of NIV in more severely ill patients is not as categorical. It 
must be kept in mind that earlier studies compared institution 
of NIV versus standard medical therapy, and not NIV versus 
endotracheal intubation. Most of the patients with advanced 
acidemia and/or severe hypercapnia had either been excluded 
in these studies and wherever they were included the results 
were nowhere as spectacular. The study by Squadrone and 
colleagues (2004), where relative effectiveness of NIV was 
compared to endotracheal intubation with conventional 
mechanical ventilation, is a case in point. All patients in 
this study had severe acidemia and hypercapnia, had failed 
medical therapy and were deemed to require mechanical 
ventilation. The outcomes of these patients were compared 
with matched historical controls managed using conventional 
approaches in the same ICU. A high rate of NIV failure was 
documented (40/64, 62.5%) and the duration of mechanical 
ventilation, ICU and hospital stay as well as mortality was not 
different. Nonetheless, this study has been criticized for the 
relatively low mean inspiratory pressures used during NIV 
institution (14.8 ± 2.6 cm H2O in the NIV group) which may 
have been responsible for a high rate of NIV failure. It is no 
surprise then that a signiﬁ  cant body of data supports early 
and routine use of NIV only in a subgroup of patients with 
AECOPD (Carlucci et al 2001; Nevins and Epstein 2001; 
Esteban et al 2002).
Apart from this, presence of several other conditions 
may prohibit use of NIV. Table 3 enlists the various contra-
indications to use of NIV. However, more recently some data 
has been forthcoming on the role of NIV in patients with most 
severe forms of AECPD. Gonzales and colleagues (2005) 
and Scala and colleagues (Scala et al 2005) showed that NIV 
may be used successfully in patients with hypercapnic coma, 
and have widened the scope of use of NIV in patients with 
exacerbation of COPD. Nonetheless, more data needs to be 
gathered, and as of now, physicians must carefully weigh 
the beneﬁ  ts of NIV use in these patients against the risks of 
delaying endotracheal intubation.
Another contentious issue regarding the safety of NIV 
use has been the site of use of NIV. Most of the above cited 
data is from patients admitted to the ICU, and clearly there 
is advantage of early NIV use over standard medical therapy. 
On the other hand, Wood and colleagues (1998) found that 
use of NIV in the emergency department delayed intubation 
and increased mortality. Similarly, Barbe and colleagues 
(1996), in their study on the use of NIV in emergency depart-
ment (ED) for patients with AECOPD, concluded that NIV 
did not seem to have a role in the recovery of these patients 
from the acute respiratory failure, and recommended against 
its routine use in the ED. However, in a large, well planned 
study (n = 236), Plant and colleagues (2000) showed that 
Table 3 Contraindications to use of noninvasive ventilation
• Uncooperative/obtunded  patient
• Agitated  patient
•  Hemodynamic instability or presence of organ failure
• Severe  comorbidity
•  Recent facial/upper airway trauma
•  Recent upper gastrointestinal tract surgery
• Intestinal  obstruction
•  Excessive secretions in the airways
• Undrained  pneumothoraxInternational Journal of COPD 2008:3(3) 355
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use of NIV in mild to moderately acidotic patients with 
COPD (pH  7.25) in the general wards was associated 
with improvement in blood gas parameters and a reduction 
in the need of endotracheal intubation, as well as in-hospital 
mortality. Therefore, it has been recommended that in the 
presence of fully trained staff and monitoring facilities, the 
use of NIV may be extended to patients with up to moder-
ate level of acidemia (ph  7.25) in the respiratory wards 
(British Thoracic Society Standards of Care Committee 2002; 
Lightowler et al 2003).
Given that NIV works and is successful in large number 
of acidotic and hypercapnic AECOPD patients, signiﬁ  cant 
number of patients still fail NIV, and the reported failure 
rates vary from 5%–40% (Bott et al 1993; Kramer et al 1995; 
Brochard et al 1995; Celikel et al 1998), though the more 
recent studies suggest lower failure rates (Carratù et al 2005). 
The obvious question is who are the patients that tend to fail 
NIV? It is pertinent to identify these patients, as a delay in 
intubation in a patient who is eventually going to need one 
is clearly associated with increased mortality. It has been 
determined that the clinical condition of the patient and the 
early response to NIV in terms of change in pH in the ﬁ  rst 
hour of ventilation are important determinants of success 
or failure (Meduri et al 1991; Ambrosino et al 1995; Plant 
et al 2001; Phua et al 2005). Apart from this, some of the 
baseline characteristics, such as a high APACHE II score, 
high basal heart rate and presence of pneumonia are also 
independently associated with failure of NIV (Khilnani et al 
2006). It is therefore recommended that patients should be 
carefully selected, and must be closely watched during the 
initial hour after initiation of NIV and the partial pressure 
of carbon dioxide (PaCO2), and pH should be monitored to 
assess the response. Only those showing clear improvement 
should be continued on the NIV.
Later management of patients 
with AECOPD
As compared with other causes of acute respiratory failure, 
patients with COPD tend to have higher rates of ventilator 
dependence, weaning failures, and reintubation (Schonhofer 
et al 2001). Many of the patients tend to have repeated wean-
ing failures and postextubation respiratory distress. They 
seem unable to support their ventilatory requirement on their 
own, develop hypercapnia and have to be intubated again. In 
fact, in a study conducted at our center, we found that a rise 
in PaCO2 from in the initial 12 hours after extubation was an 
independent predictor of need of reintubation (Khilnani et al 
2006). Also, it is well known that reintubation is associated 
with increased morbidity and mortality in patients with 
COPD (Epstein et al 1997; Khilnani et al 2006). NIV has 
been used as a bridge to support patients after extubation 
until such a time as they are able to support themselves 
and breathe spontaneously (Hilbert et al 1998; Nava et al 
1998). In a recent study of difﬁ  cult to wean patients, use of 
an NIV-based multidisciplinary approach was found to be 
extremely useful (success rate of 95%) in the weaning of 
these patients (Quinnell et al 2006). In these studies, NIV sup-
port was offered to the patient immediately after extubation, 
and this was associated with improved outcome in terms of 
need of reintubation as well as mortality. However, in a more 
recent study, Keenan and colleagues (2002) evaluated the role 
of NIV in patients who developed postextubation respiratory 
distress within 48 hours. It was observed that there was no 
difference in the rates of reintubation or hospital mortality, 
and the authors concluded that NIV cannot be recommended 
in this setting. It is therefore prudent to consider early use 
of NIV in patients with COPD who are extubated, possibly 
as soon as the endotracheal tube is removed. In fact, in a 
tracheostomized patient, NIV may be initiated using a nasal 
mask with the cuff of the tube deﬂ  ated. If patient is unable 
to tolerate weaning, one can switch back to conventional 
ventilation very easily.
NIV for severe stable COPD
Role of nocturnal NIV use has also been evaluated in long 
term management of patients with severe/very severe COPD. 
Whereas some evidence does justify use in this situation, the 
quality as well as quantity of the data supporting use of NIV 
in this situation is clearly inferior to that in acute setting. 
In a small uncontrolled trial, Keilty and colleagues (1994) 
showed that use of inspiratory pressure support improved 
median walking distance by 62% in patients with severe 
COPD with disabling breathlessness. This was followed by 
data that showed that long term use of nocturnal NIV was 
associated with improvements in physiological parameters 
including blood gas data and pulmonary hyperinﬂ  ation 
as well as subjective symptom scores (Leger et al 1994; 
Jones et al 1998; Budweiser et al 2005). On the other hand, 
Schönhofer and colleagues (2007) reported that use of NIV 
lead to improvement in exercise endurance in patients with 
chronic respiratory failure secondary to thoracorestriction 
but not in patients with COPD. However, minute ventilation 
of COPD patients improved with consequent reduction in 
PaCO2 (Schonhofer et al 2008). Clini and colleagues (2002) 
recently showed that NIV lead to improvements in dyspnea 
as well as health related quality of life. The obvious question International Journal of COPD 2008:3(3) 356
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that remains is whether NIV actually improves the long term 
survival of patients with COPD.
Not many studies have attempted to answer this question. 
Clini and colleagues (1998) addressed this issue in their 
study of 49 stable hypercapnic COPD patients (very severe 
COPD) on long term oxygen therapy (LTOT). Patients were 
randomly assigned to usual LTOT alone versus LTOT with 
nocturnal pressure support ventilation. Whereas the use of 
pressure support ventilation was associated with improved 
exercise capacity and reduced ICU admissions, it did not 
prolong survival over a period of three years. The same group 
published their results for a larger study addressing the same 
issue, and concluded with similar results (Clini et al 2002).
More recently some more data has been forthcoming on 
the long term beneﬁ  ts of NIV. Budweiser and colleagues 
(Budweiser et al 2007a) compared the long-term survival 
of 140 patients with severe persistent hypercapnic COPD 
with (n = 99) or without (n = 41) NIV. It was found that 
survival rates were signiﬁ  cantly higher in patients with NIV 
compared to those without this therapy (one and two year 
survival rates 87.7% and 71.8%, respectively, in patients 
on NIV vs. 56.7% and 42.0% in patients without NIV; 
p = 0.001). Beneﬁ  cial effects were particularly seen in 
patients with base excess 8.9 mmol/l, pH 7.41, forced 
expiratory volume in one second 27.5%, hemoglobin 
13.8 g/dl or large hyperinﬂ  ation (residual volume-to-total 
lung capacity 189% predicted) (Budweiser et al 2007a). 
Moreover, predictors of mortality in this subset of COPD 
patients being managed with long term NIV were also 
reported by the same group (Budweiser et al 2007b). Survival 
rates of 188 COPD patients on NIV at 1-year, 2-years, and 
5-years were found to be 84.0%, 65.3%, and 26.4% respec-
tively. Malnutrition, hyperinﬂ  ation and base excess emerged 
as the independent predictors of mortality.
Clearly, the data on mortality beneﬁ  t of NIV use in long 
term management of severe COPD is not robust enough to 
justify the routine use of NIV for home ventilation. How-
ever, given the positive impact of nocturnal use of NIV on 
physiological parameters as well subjective symptoms, there 
is signiﬁ  cant beneﬁ  t in terms of reduction of morbidity and 
possibly mortality. Larger studies designed to determine the 
impact of NIV on long term mortality in these patients are 
required, and a routine use of NIV must await such data.
Conclusions
Use of NIV, especially in the early course of the disease, has 
revolutionized the management of patients with AECOPD. It 
is clearly a superior alternative to standard medical therapy 
during the initial phase of management of these patients. 
NIV should be considered for all the patients unless there is a 
contraindication to its use. It should be avoided in extremely 
sick, hemodynamically unstable and obtunded patients, who 
are better managed by invasive conventional mechanical ven-
tilation. Data on use in markedly hypercapnic or severely aci-
dotic patients is sparse, but future studies may address these 
issues. All patients initiated on NIV must be closely watched 
for the initial period as early response tends to predict success 
of the intervention. NIV is also a viable option for weaning 
of patients with AECOPD. Again, early rather than late use 
is associated with better outcomes. Long term nocturnal 
use of NIV in patients with very severe COPD is useful in 
improving blood gas parameters, dyspnea and quality of life 
and may also favorably impact long term survival.
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